Five studies. Designs before conclusions.
A source-linked guide to what five important research programs registered, planned, or measured, and what their designs cannot establish. No outcome league table and no efficacy promise.
Start with design and recruitment relevance, then open a study for its population, comparator, follow-up, outcome focus, limitations, and primary source. Planned programs are clearly separated from completed research. A listed recruiting status is not a guarantee of an open place or eligibility.
5 of 5 records shown
University of California, Irvine
Outcome focus: Changes in reward-circuit functional connectivity, drug-cue BOLD activation, regional glutamate and glutamine, EEG alpha power, opioid withdrawal, and craving
What it suggests: The registered assessments can characterize neural and self-reported changes before and after independently obtained ibogaine treatment in a defined OUD cohort
DemeRx, Inc.
Outcome focus: Clinical development of DMX-1001, an oral noribogaine candidate, for alcohol use disorder; no registered outcome set is cited in the announcement
What it suggests: DemeRx announced FDA acceptance of its Investigational New Drug application in April 2026, permitting the described development program to proceed toward further study
Stanford University
Outcome focus: Change in WHODAS 2.0 disability and functioning scores; the broader editorial record also describes clinical and neuroimaging assessments
What it suggests: The study provides prospectively collected before-and-after measurements in a defined veteran cohort and a registered framework for examining functioning and disability
UTHealth Houston, selected by Texas Health and Human Services Commission as lead institution
Outcome focus: Program-level development of controlled ibogaine research; no study-specific registered outcome set is identified in the cited program source
What it suggests: Texas has selected UTHealth Houston to lead implementation of Senate Bill 2308 and is developing the institutional path for future ibogaine clinical trials
International Center for Ethnobotanical Education, Research, and Service, with Hospital Universitari Sant Joan de Reus and other listed collaborators
Outcome focus: Rate of methadone dose decrease, adverse events at different doses, and electrocardiogram measures including QT interval and ST wave
What it suggests: The registry documents completion of a small, masked, randomized dose-comparison study with defined methadone-taper and safety outcomes under hospital monitoring
A reading guide, not a ranking
Observational cohorts can document what changed over time, but without a suitable comparator they cannot isolate causation. Randomization and masking answer different questions, but a small completed trial still needs a results source before anyone can interpret its findings.
A registry status-verification date comes from the study sponsor's registry record. An update-posted date comes from the registry. An editorial review date records when this Atlas checked and summarized the cited evidence. None should be presented as a substitute for another.